Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H (3378) Financial Statements
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H Financial Overview
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H's market cap is currently $3.86B. The company's EPS TTM is $0.12; its P/E ratio is 85.77; and it has a dividend yield of 0.00%. Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 21 | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 25.69B | $ 17.69B | $ 13.93B | $ 12.92B | $ 12.92B |
| Gross Profit | $ 1.38B | $ 1.23B | $ 1.26B | $ 1.22B | $ 1.20B |
| Operating Income | $ 1.20B | $ 770.54M | $ 759.37M | $ 809.02M | $ 855.84M |
| EBITDA | $ 1.29B | $ 1.90B | $ 1.91B | $ 1.51B | $ 1.45B |
| Net Income | $ 769.11M | $ 616.58M | $ 668.76M | $ 554.39M | $ 819.60M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 3.90B | $ 3.04B | $ 2.89B | $ 1.61B | $ 1.05B |
| Total Assets | $ 26.47B | $ 24.00B | $ 22.93B | $ 21.25B | $ 20.91B |
| Total Debt | $ 11.98B | $ 7.57B | $ 7.68B | $ 6.53B | $ 6.14B |
| Net Debt | $ 9.01B | $ 6.86B | $ 5.80B | $ 5.85B | $ 5.47B |
| Total Liabilities | $ 15.81B | $ 11.40B | $ 10.56B | $ 9.28B | $ 9.07B |
| Stockholders' Equity | $ 5.89B | $ 5.83B | $ 5.65B | $ 5.36B | $ 5.22B |
| Cash Flow | |||||
| Free Cash Flow | $ 1.92B | $ 868.71M | $ 659.50M | $ 70.47M | $ 74.67M |
| Operating Cash Flow | $ 1.92B | $ 1.42B | $ 1.35B | $ 909.52M | $ 667.10M |
| Investing Cash Flow | $ -2.55B | $ -1.98B | $ -779.46M | $ -802.93M | $ -717.14M |
| Financing Cash Flow | $ 2.88B | $ -607.72M | $ 627.06M | $ -97.74M | $ -417.48M |
Currency in CNY
